Tempus AI Completes Acquisition of Ambry Genetics to Advance Precision Medicine

2 min read | February 04, 2025 01:57 AM PST | By Team Kalkine Media

Tempus AI Completes Acquisition of Ambry Genetics to Advance Precision Medicine — Image source: shutterstock

Strengthening AI-Driven Healthcare

The acquisition marks a strategic step for Tempus in expanding its role in AI-powered precision medicine. By integrating Ambry’s genetic testing expertise, Tempus aims to enhance patient care through data-driven insights into genetics and disease relationships.

“This acquisition aligns with our mission to bring cutting-edge AI and genomic insights to healthcare,” said a Tempus spokesperson. “Ambry’s capabilities will strengthen our ability to personalize treatment and improve patient outcomes.”

Ambry Genetics to Operate as a Subsidiary

Ambry Genetics will continue to function as a wholly-owned subsidiary of Tempus under its current leadership team. This ensures continuity in its genetic testing operations while leveraging Tempus’ AI capabilities for broader innovation in healthcare.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.